Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - A monocentric analysis.
COVID-19
ITP
immune thrombocytopenia
thrombocytopenia
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
15
01
2023
received:
20
10
2022
accepted:
25
01
2023
medline:
6
4
2023
pubmed:
17
2
2023
entrez:
16
2
2023
Statut:
ppublish
Résumé
Immune thrombocytopenia (ITP) was reported as a rare complication of COVID-19 vaccines. We conducted a retrospective single-center analysis of all ITP cases detected in 2021 and compared the quantity with the pre-vaccination years, from 2018 to 2020. In 2021, a two-fold increase in ITP cases was identified compared to previous years; 11 of 40 cases (27.5%) were considered COVID-19-vaccine related. Our study highlights an increase in ITP cases at our institution, probably related to COVID-19 vaccinations. Further studies are needed to investigate this finding globally.
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-226Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021;27(7):1290-7.
Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021;397(10285):1646-57.
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.
EMA. COVID-19 vaccines safety update 2022. Available from: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-14-july-2022_en.pdf.
Paulsen F-O, Schaefers C, Langer F, Frenzel C, Wenzel U, Hengel FE, et al. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19). Blood. 2021;138:996-9.
Lee E-J, Beltrami-Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, et al. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022;139(10):1564-74.
Kewan T, Gunaratne TN, Mushtaq K, Alayan D, Daw H, Haddad A. Outcomes and management of immune thrombocytopenia secondary to COVID −19: Cleveland clinic experience. Transfusion. 2021;61(7):2014-8.
Matzdorff A, Holzhauer S, Kühne T, Meyer O, Ostermann H, Pabinger-Fasching I, Rummel MJ, Sachs U, Wörmann B. Leitlinie Immunthrombozytopenie (ITP). 2021.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93.
Sjoberg DD, Whiting K, Curry M, Lavery AJ, Larmarange J. Reproducible summary tables with the gtsummary package. The R Journal. 2021;13(1):570.
Visser C, Swinkels M, Van Werkhoven ED, Croles FN, Noordzij-Nooteboom HS, Eefting M, et al. COVID-19 vaccination in patients with immune thrombocytopenia. Blood Adv. 2022;6(6):1637-44.